Assay
Financial-condition grades for SEC filers
Company Report · as of Oct 9, 2026
|
| NutriBand Inc.NTRB · healthcare | |
|---|---|
| Grade |  Dfourth fifth of 371 graded peers; percentile 75.0, sampling error 2.5 points; lower is stronger |
| Rank | 278 of 371 |
| Profitability | Cpercentile 52.8 |
| Solvency | Cpercentile 49.8 |
| Growth and financing | Dpercentile 68.8 |
| Reliability | 0.76 AUCfailure model, filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025 |
| Peer failure rate | 0.60% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025 |
| Size band | under $12.5M assetstotal assets $7.5M[1] |
| Standard universe | outsiderevenue above $1M and assets above $10M[1-2] |
| Warnings | none active · fortress balance sheetnot computable: dilution, distress |
| Inputs computable | 7 of 14 |
| Graded from | filings received through May 18, 2026144 days before the rescan; every figure keyed to the SEC receipt date |
| Last close | $6.082026-10-08; market equity $0; iex feed |
| Price used in grade | None |
| Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date. Open this report as it stood on | ||||||||||||||||||||||||||||||||
Each date opens the report as it stood on that rescan. |
Business, in the company's words. Opening of Item 1 of the 10-K received Apr 29, 2026; the document on sec.gov.
“we” or “us”), was incorporated in Nevada in January 2016. Our primary business is the development of a portfolio of transdermal pharmaceutical products. Our development pipeline primarily consists of transdermal products that are based on our proprietary AVERSA™ abuse deterrent transdermal technology that we believe can be incorporated into existing transdermal patches that contain drugs that are susceptible to abuse and misuse such as opioid and stimulant drugs. services through our subsidiaries Pocono Pharmaceuticals operating as Active Intelligence and 4P Therapeutics.
Warnings [top]
7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.
The Fourteen Inputs [top]
Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.
| Input | Percentile, 0 to 100 | Value | Source | Peer median | Percentile | Peers | Period end |
|---|---|---|---|---|---|---|---|
| Profitability, sleeve percentile 52.8 | |||||||
| Gross profitability | 7.5% | [1,5] | 32.2% | 79.4 | 372 | 2026-01-31 | |
| Return on invested capital | not computable | 9.3% | |||||
| one or more required annual facts are missing | |||||||
| Accruals ratio | (41.2%) | [1,6-8] | (6.6%) | 10.6 | 811 | 2026-01-31 | |
| Gross margin stability, five years | 4.6 pts | [2,5,9-16] | 2.8 pts | 68.4 | 243 | 2026-01-31 | |
| Solvency, sleeve percentile 49.8 | |||||||
| Twelve-month failure probability | not computable | 0.07% | |||||
| firm-wide XBRL shares cannot be assigned to one ticker class | |||||||
| Altman Z double-prime | (15.84) | [1,17-22] | (0.31) | 70.5 | 756 | 2026-01-31 | |
| Net debt to EBITDA | not computable | 1.82x | |||||
| required facts have no common fiscal period end | |||||||
| Interest coverage | not computable | (4.51x) | |||||
| interest expense must exceed $100,000 | |||||||
| Current ratio | 6.36x | [17-18] | 2.96x | 29.1 | 839 | 2026-01-31 | |
| Growth and financing, sleeve percentile 68.8 | |||||||
| Revenue growth, three-year compound | (0.7%) | [2,10-11,14] | 10.0% | 72.6 | 415 | 2026-01-31 | |
| Free cash flow growth, three-year compound | not computable | 10.9% | |||||
| current FCF must be positive and base FCF must exceed $100,000 | |||||||
| Reinvestment rate | not computable | 37.1% | |||||
| one or more required annual facts are missing | |||||||
| Asset growth, three years | (7.2%) | [1,8,23-24] | 2.1% | 65.1 | 704 | 2026-01-31 | |
| Net share issuance, one year | not computable | 2.5% | |||||
| firm-wide XBRL shares cannot be assigned to one ticker class | |||||||
Gross profitability. Revenue less cost of goods sold, over total assets.
Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.
Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.
Twelve-month failure probability. CHS model; lower is stronger.
Net debt to EBITDA. Lower is stronger.
Net share issuance, one year. Split-adjusted; lower is stronger.
Sleeves are equal-weighted; within a sleeve each computable input carries equal weight. Composite 0.148; sampling error 2.5 percentile points on 371 peers.
Among 371 Peers [top]
Composite score of every graded peer, smoothed. Vertical rules are the letter band edges at the 20th, 40th, 60th and 80th percentiles. Small dots are the six largest peers by market equity.
| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 273 | Butterfly Network, Inc. (BFLY) Butterfly Network, Inc. (BFLY) Dfourth fifth; percentile 73.5 NYSE · X-Ray Apparatus & Tubes & Related Irradiation Apparatus last close $8.02 No active warnings; 7 of 14 inputs | 73.5 | D | |
| 274 | Vir Biotechnology, Inc. (VIR) Vir Biotechnology, Inc. (VIR) Dfourth fifth; percentile 73.8 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $1.9B; last close $11.12 No active warnings; 9 of 14 inputs | 73.8 | D | |
| 275 | Viatris Inc. (VTRS) Viatris Inc. (VTRS) Dfourth fifth; percentile 74.1 Nasdaq · Pharmaceutical Preparations market equity $20.0B; last close $17.44 No active warnings; 10 of 14 inputs | 74.1 | D | |
| 276 | Precision Optics Corporation, Inc. (POCI) Precision Optics Corporation, Inc. (POCI) Dfourth fifth; percentile 74.3 Nasdaq · Electromedical & Electrotherapeutic Apparatus market equity $51.2M; last close $4.59 Warnings: dilution, fortress balance sheet; 8 of 14 inputs | 74.3 | D | dilution, fortress balance sheet |
| 277 | Retractable Technologies Inc. (RVP) Retractable Technologies Inc. (RVP) Dfourth fifth; percentile 74.6 NYSE · Surgical & Medical Instruments & Apparatus market equity $19.8M; last close $0.68 Warnings: fortress balance sheet; 8 of 14 inputs | 74.6 | D | fortress balance sheet |
| 278 | NutriBand Inc. (NTRB) NutriBand Inc. (NTRB) Dfourth fifth; percentile 75.0 Nasdaq · Orthopedic, Prosthetic & Surgical Appliances & Supplies last close $6.08 Warnings: fortress balance sheet; 7 of 14 inputs | 75.0 | D | fortress balance sheet |
| 279 | NutriBand Inc. (NTRBW) NutriBand Inc. (NTRBW) Dfourth fifth; percentile 75.0 Nasdaq · Orthopedic, Prosthetic & Surgical Appliances & Supplies last close $0.92 Warnings: fortress balance sheet; 7 of 14 inputs | 75.0 | D | fortress balance sheet |
| 280 | Teleflex Inc. (TFX) Teleflex Inc. (TFX) Dfourth fifth; percentile 75.4 NYSE · Surgical & Medical Instruments & Apparatus market equity $5.3B; last close $124.12 No active warnings; 10 of 14 inputs | 75.4 | D | |
| 281 | Standard Biotools Inc. (LAB) Standard Biotools Inc. (LAB) Dfourth fifth; percentile 75.7 Nasdaq · Pharmaceutical Preparations market equity $263.1M; last close $0.67 Warnings: late filer, fortress balance sheet; 7 of 14 inputs | 75.7 | D | late filer, fortress balance sheet |
| 282 | Abeona Therapeutics Inc. (ABEO) Abeona Therapeutics Inc. (ABEO) Dfourth fifth; percentile 75.9 Nasdaq · Pharmaceutical Preparations market equity $283.6M; last close $4.95 Warnings: fortress balance sheet; 9 of 14 inputs | 75.9 | D | fortress balance sheet |
| 283 | Cytosorbents Corp. (CTSO) Cytosorbents Corp. (CTSO) Dfourth fifth; percentile 76.2 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $234.4M; last close $3.80 Warnings: short runway, fortress balance sheet; 7 of 14 inputs | 76.2 | D | short runway, fortress balance sheet |
| Peer policy | Letter | Percentile | Peers |
|---|---|---|---|
| all graded filers, equal sleeves | D | 74.9 | 2204 |
| sector peers, equal sleeves (the grade) | D | 75.0 | 371 |
| same exchange, equal sleeves | D | 72.0 | 1219 |
| sector peers, equal inputs | D | 73.9 | 371 |
Each letter is one fifth of the 371 graded peers, about 74 companies. A boundary letter (A/B, B/C, C/D, D/E) marks a percentile within one sampling error of a band edge.
What the Price Implies [top]
Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.
| Measure | Value | Peer median | Percentile | Reading |
|---|---|---|---|---|
| Twelve-month price change, skipping the latest month | (38.1%) | 8.0% | 18 | hotter than 18 of 100 peers |
| Distance from 52-week high | (32.7%) | (31.4%) | 47 | closer to its high than 47 of 100 peers |
| EBIT to enterprise value | not computable | (1.5%) | required accounting or market input is missing | |
| Free cash flow yield | not computable | (1.0%) | required accounting or market input is missing | |
| Book value to price | not computable | 0.28 | required accounting or market input is missing | |
| Sales to price | not computable | 0.31 | required accounting or market input is missing | |
| Composite equity issuance, five years | not computable | 20.3% | required accounting or market input is missing | |
| Relative strength against the sector, log excess return | (0.69) | (0.14) | 18 | ahead of 18 of 100 peers |
Inputs: EBIT -$8.3M; free cash flow -$5.1M; book equity $5.3M; sales $2.0M; debt $1,820; cash $3.4M[25].
Diagnostics [top]
Diagnostics do not feed the grade.
| Piotroski F-score: None of 9, period end 2026-01-31 | ||
|---|---|---|
| Return on assets above zero | (110.2%) | ✗ fail[6,8] |
| Operating cash flow above zero | -$5.1M | ✗ fail[7] |
| Return on assets improved | 29.3 pts | ✓ pass[6,8,23,26] |
| Operating cash flow exceeds net income | $3.1M | ✓ pass[6-7] |
| Long-term leverage fell | n/a[1,8,23] | |
| Current ratio improved | 148.3 pts | ✓ pass[17-18,27-28] |
| No new shares issued | n/a | |
| Gross margin improved | (6.9 pts) | ✗ fail[2,5,9-10] |
| Asset turnover improved | (1.2 pts) | ✗ fail[2,8,10,23] |
Downloads [top]
|
Sources [top]
Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.
| # | Concept | XBRL tag | Value | Period end | Received | Form | Links |
|---|---|---|---|---|---|---|---|
| 1 | assets | us-gaap:Assets | $7.5M | 2026-01-31 | 2026-04-29 | 10-K | filing · viewer · series |
| 2 | revenue | us-gaap:Revenues | $2.0M | 2026-01-31 | 2026-04-29 | 10-K | filing · viewer · series |
| 3 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $27,124 | 2017-01-31 | 2019-04-19 | 10-K | filing · viewer · series |
| 4 | total debt | us-gaap:LongTermDebt | $1,581 | 2017-01-31 | 2018-05-01 | 10-K | filing · viewer · series |
| 5 | gross profit | us-gaap:GrossProfit | $566,308 | 2026-01-31 | 2026-04-29 | 10-K | filing · viewer · series |
| 6 | net income | us-gaap:NetIncomeLoss | -$8.2M | 2026-01-31 | 2026-04-29 | 10-K | filing · viewer · series |
| 7 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$5.1M | 2026-01-31 | 2026-04-29 | 10-K | filing · viewer · series |
| 8 | assets | us-gaap:Assets | $7.5M | 2025-01-31 | 2026-04-29 | 10-K | filing · viewer · series |
| 9 | gross profit | us-gaap:GrossProfit | $743,317 | 2025-01-31 | 2026-04-29 | 10-K | filing · viewer · series |
| 10 | revenue | us-gaap:Revenues | $2.1M | 2025-01-31 | 2026-04-29 | 10-K | filing · viewer · series |
| 11 | revenue | us-gaap:Revenues | $2.1M | 2024-01-31 | 2025-04-28 | 10-K | filing · viewer · series |
| 12 | cost of revenue | us-gaap:CostOfRevenue | $1.2M | 2024-01-31 | 2025-04-28 | 10-K | filing · viewer · series |
| 13 | gross profit | us-gaap:GrossProfit | $750,404 | 2023-01-31 | 2023-04-26 | 10-K | filing · viewer · series |
| 14 | revenue | us-gaap:Revenues | $2.1M | 2023-01-31 | 2024-05-01 | 10-K | filing · viewer · series |
| 15 | gross profit | us-gaap:GrossProfit | $554,310 | 2022-01-31 | 2023-04-26 | 10-K | filing · viewer · series |
| 16 | revenue | us-gaap:Revenues | $1.4M | 2022-01-31 | 2023-04-26 | 10-K | filing · viewer · series |
| 17 | current assets | us-gaap:AssetsCurrent | $5.0M | 2026-01-31 | 2026-04-29 | 10-K | filing · viewer · series |
| 18 | current liabilities | us-gaap:LiabilitiesCurrent | $784,281 | 2026-01-31 | 2026-04-29 | 10-K | filing · viewer · series |
| 19 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$46.7M | 2026-01-31 | 2026-04-29 | 10-K | filing · viewer · series |
| 20 | operating income | us-gaap:OperatingIncomeLoss | -$8.3M | 2026-01-31 | 2026-04-29 | 10-K | filing · viewer · series |
| 21 | book equity | us-gaap:StockholdersEquity | $6.7M | 2026-01-31 | 2026-04-29 | 10-K | filing · viewer · series |
| 22 | liabilities | us-gaap:Liabilities | $868,447 | 2026-01-31 | 2026-04-29 | 10-K | filing · viewer · series |
| 23 | assets | us-gaap:Assets | $7.5M | 2024-01-31 | 2025-04-28 | 10-K | filing · viewer · series |
| 24 | assets | us-gaap:Assets | $9.5M | 2023-01-31 | 2024-05-01 | 10-K | filing · viewer · series |
| 25 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 12,155,683 | 2026-09-04 | 2026-09-04 | 10-Q | filing · viewer · series |
| 26 | net income | us-gaap:NetIncomeLoss | -$10.5M | 2025-01-31 | 2026-04-29 | 10-K | filing · viewer · series |
| 27 | current assets | us-gaap:AssetsCurrent | $4.8M | 2025-01-31 | 2026-04-29 | 10-K | filing · viewer · series |
| 28 | current liabilities | us-gaap:LiabilitiesCurrent | $982,845 | 2025-01-31 | 2026-04-29 | 10-K | filing · viewer · series |
| 29 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $3.4M | 2026-07-31 | 2026-09-04 | 10-Q | filing · viewer · series |
| 30 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$1.1M | 2026-07-31 | 2026-09-04 | 10-Q | filing · viewer · series |
| 31 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$563,104 | 2026-04-30 | 2026-06-11 | 10-Q | filing · viewer · series |
| 32 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$4.4M | 2025-10-31 | 2025-12-11 | 10-Q | filing · viewer · series |
| 33 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$2.7M | 2025-07-31 | 2026-09-04 | 10-Q | filing · viewer · series |
Limitations [top]
Grade boundary. Percentile 75.0 is 5.0 points from the nearest band edge; sampling error is 2.5 points.
Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.
Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.
Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.
Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.
Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
